Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin–eosin-based morphologic parameters from the WHO classification

BACKGROUND: Immunohistochemical loss of CDX2 has been proposed as a biomarker of dismal survival in colorectal carcinoma (CRC), especially in UICC Stage II/III. However, it remains unclear, how CDX2 expression is related to central hematoxylin–eosin (HE)-based morphologic parameters defined by 2019...

Descripción completa

Detalles Bibliográficos
Autores principales: Konukiewitz, Björn, Schmitt, Maxime, Silva, Miguel, Pohl, Junika, Lang, Corinna, Steiger, Katja, Halfter, Kathrin, Engel, Jutta, Schlitter, Anna Melissa, Boxberg, Melanie, Pfarr, Nicole, Wilhelm, Dirk, Foersch, Sebastian, Tschurtschenthaler, Markus, Weichert, Wilko, Jesinghaus, Moritz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651779/
https://www.ncbi.nlm.nih.gov/pubmed/34616012
http://dx.doi.org/10.1038/s41416-021-01553-0

Ejemplares similares

Ejemplares similares